Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer

Christian C. Okoye¹, C. Jane Cho², Mitchell Liu³, Alexander V. Louie⁴, Olusola Obayomi-Davies⁵, Shankar Siva⁶, Simon S. Lo³

¹Department of Radiation Oncology, St. Bernards Medical Center, Jonesboro, AR, USA; ²Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA; ³BC Cancer-Vancouver Clinic, Vancouver, Canada; ⁴Department of Radiation Oncology, Sunnybrook Health Science Centre, Toronto, ON, Canada; ⁵Department of Radiation Oncology, WellStar Medical Group, Marietta, GA, USA; ⁶Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

Correspondence to: Simon Lo, MB, ChB, FACR, FASTRO. Professor & Vice Chair for Strategic Planning, Director of Stereotactic Body Radiation Therapy, Professor of Neurological Surgery, UW School of Medicine, Department of Radiation Oncology, 1959 NE Pacific St., Seattle, WA 98195, USA. Email: simonslo@uw.edu.

Provenance and peer review: This article was commissioned by the editorial office, Annals of Translational Medicine. The article did not undergo external peer review.


Submitted Apr 06, 2020. Accepted for publication Apr 17, 2020. doi: 10.21037/atm-20-3149

View this article at: http://dx.doi.org/10.21037/atm-20-3149

For patients with early-stage, node-negative non-small cell lung cancer (NSCLC), stereotactic body radiation therapy (SBRT) has been a welcome addition as a non-invasive, curative treatment option for appropriately selected patients. It has evolved from an abundance of literature demonstrating higher tumor control with higher biologically equivalent doses (BED) of radiation along with improvements in patient evaluation and staging, patient setup and motion management, treatment planning, image guidance, radiation delivery, and understanding of relevant, dose-related toxicities. However, the dose-fractionation schemes of SBRT for early-stage NSCLC remain loosely defined and are based largely on toxicity, with the implicit assumption that all regimens are similarly effective.

In the seminal paper by Onishi et al., patients with stage I NSCLC treated with various SBRT schedules were found to have lower rates of locoregional recurrence and improved overall survival (OS) with BED of greater than 100 Gy₁₀ (1). Additional studies have confirmed these results and established the superiority of doses greater than 100 Gy₁₀ and attempts at curing patients with early-stage NSCLC aim to achieve these doses. While similar BED₁₀ doses can be achieved over more than 5 fractions (e.g., 60 Gy in 8 fractions), as is commonly done outside of the United States, recent ASTRO guidelines consider these regimens as alternatives to treatment schedules with 5 or fewer fractions (2). What remains unclear is whether calculating a BED₁₀ is an accurate method for stratifying the efficacy of SBRT regimens (3), and if so, whether there are any significant differences in outcomes associated with BED₁₀.

Moreno et al. attempt to address the latter question in their recent publication (4). Specifically, the authors used the National Cancer Database (NCDB) to identify patients treated with SBRT as a curative intent modality for a clinical stage I (T1-2aN0 per AJCC 7th edition) NSCLC to investigate whether a higher BED₁₀ is associated with improved survival outcomes. They were unable to directly account for tumor centrality, a known confounder, but attempted to account for this by limiting cohort to those receiving at least 100 Gy₁₀. Initially, an exploratory analysis was used to determine the appropriate BED₁₀ cutoff relative to OS; subsequently, patients were dichotomized by BED₁₀, with low BED corresponding to 100–129 Gy₁₀ and high BED corresponding to doses 130 Gy₁₀ and above. The cohort was further refined through 1:1 propensity score-matching, with BED₁₀ stratification and age at diagnosis,
comorbidity, tumor size, tumor histology, and tumor location as covariates.

With a median follow up of 26 months, 5-year OS rates between propensity-matched high and low BED cohorts were 34% and 26% (P=0.039), respectively, and on multivariate analysis, receipt of low BED was associated with significantly worse survival (HR 1.046, P=0.032). Low BED regimens became more common over the study period corresponding with key publications in the literature. The authors concluded that high BED regimens may confer a survival benefit, low BED regimens have become more common clinically, and additional studies are needed to determine the dose-response and associated toxicities of high BED regimens.

This work provides valuable insight into the role of SBRT in clinical practice and extend the work of Koshy et al. in a previous NCDB analysis (5). In that study, 498 patients with T1-2N0 NSCLC treated with SBRT from an earlier era (2003–2006) were similarly evaluated for the correlation between BED$_{10}$ (dichotomized at 150 Gy BED$_{10}$) and OS. Through their analysis, a significant interaction was detected between T-stage and BED$_{10}$, where the 3-year OS was no different among patients with T1 tumors while patients with T2 tumors saw a significant increase in their 3-year OS with high versus low BED treatments (37% vs. 24%, P=0.01). These differences among patients with T2 tumors persisted in multivariate analysis.

While many of the limitations in this analysis are inherent in large databases like the NCDB, strengths of this updated analysis include the very large and modern sample size that reflects current patterns of practice with propensity-matching across known and available potential confounders between treatment strategies (though differences persisted in race and facility type). The analysis also limited the patient cohort to what we would consider standard SBRT treatments in the US, including those who received BED$_{10}$ >100 Gy over three to five fractions. The primary comparison between high and low BED regimens was informed by an initial exploratory analysis of the same cohort, limiting the generalizability of the findings.

Throughout the study period, radiation target dose prescriptions and calculation methods have changed significantly. In the early 2000s, tumor doses were more often prescribed to point(s) within the target structure without heterogeneity corrections, while now, doses are almost universally prescribed to the target periphery with heterogeneity corrections. In fact, because dose-volume histogram (DVH) characteristics are evaluated for all critical structures, heterogeneity across the entire tumor volume may be used intentionally to allow for lower doses in areas immediately adjacent to organs at risks (OARs). However, the lower peripheral doses to the planning target volume (PTV) and OARs within the PTV may not be accurately captured by the prescription dose alone and the impact of marginal dose and/or tumor heterogeneity on outcomes remains incompletely understood. In summary, the lack of dosimetric data within the NCDB limits the reliability of the major dependent variable, BED$_{10}$, as the nominal prescription dose may not have the same meaning across different prescribing physicians, given the aforementioned changes in practice pattern. Prospective studies mitigate these effects by creating a homogeneous set of parameters for which the outcomes are based, while future cohort studies may instead use DVH-based dose reporting. The use of robust dose calculation methods and quality heterogeneity correction are also required to understand the actual spatial dose distribution and its effect on tumor control (6).

Several studies have evaluated the authors’ primary conclusion that higher BED$_{10}$ doses may correlate with improved OS at doses above 100 Gy$_{10}$. A meta-analysis performed by Zhang et al. in 2011 showed concern for higher doses (>146 Gy$_{10}$) causing lower survival compared to medium (83.2–106 Gy$_{10}$) and medium to high (106–146 Gy$_{10}$) doses, leading authors to conclude that medium and medium to high doses may be most appropriate (7). Mak et al. reached a similar conclusion after reviewing their institutional experience of 75 patients treated with SBRT for early-stage lung cancer, finding no significant impact of BED$_{10} \geq 151.2$ (HR 0.88, P=0.76) on freedom from any recurrence in univariate analysis (8). Ma et al. compared 3 fraction (dose, median: 60 Gy or 151 Gy$_{10}$) and 5 fraction (dose, median: 50 Gy or 94 Gy$_{10}$) regimens, and in a propensity score-matched cohort of 94 patients, no differences were observed in OS (P=0.33) or local failure (P=0.86) (9). In contrast, Kestin et al. reviewed a multi-institutional experience with T1-2N0 NSCLC, and determined an optimal BED$_{10}$ PTVmean cutpoint for local recurrence to be 125 Gy, with a corresponding 2-year local recurrence of 4% vs. 17% for PTVmean > vs. <125 Gy, respectively (10). Additionally, Zhao et al. reviewed their institutional experience with T1-2N0M0 NSCLC undergoing hypofractionated RT (70 Gy over 10 fractions) and SABR (50 Gy over 4 fractions). Cutoff values determined by receiver operating characteristic (ROC) curve analysis relating to local and/or lobar
recurrence included the minimum BED\textsubscript{10} to 95% of the PTV >86 Gy and a highly correlated PTV\textsubscript{mean} BED\textsubscript{10} >130 Gy (significant on univariate analysis; corresponds to a PTV\textsubscript{mean} physical dose of 55 Gy over 4 fractions) (11). Finally, Stephans et al. reported on patients with peripheral tumors receiving various high and low BED regimens, demonstrating reduced 2-year local failure rate with a high BED regimen (60 Gy in 3 fractions, 4.3%; 30–34 Gy in 1 fraction, 21%; 48–50 Gy in 4-5 fractions, 15.5%; 50–60 Gy in 8–10 fractions, 13.3%) without differences in nodal failure, distant failure, or OS (12).

The main drawbacks of these studies are that they are retrospective, underpowered, inclusive of BED doses below recommended limit (i.e., BED\textsubscript{10} <100 Gy), and limited capacity to account for known prognostic factors that impact tumor control and survival. The studies are also difficult to compare and apply in practice due to differences in what constitutes high and low BED regimens (with cutoffs ranging from 125 Gy\textsubscript{10} to 150 Gy\textsubscript{10}) and limited validation in independent datasets. While the data remains mixed and potentially complicated by other factors (such as tumor size, as stated below), the current study lends support toward the role for higher BED\textsubscript{10} doses in treating early-stage NSCLC, though the prospective evaluation of precise DVH metrics remains necessary to ensure the safety of such an approach.

In studies that evaluate tumor size, many confirm a significant correlation between tumor dose and tumor control that is affected by tumor size. In a registry study of early-stage lung cancer patients treated with SBRT reported by Davis et al., prescription BED\textsubscript{10} of <105, 105–149, and >150 Gy among T2 patients resulted in significant improvements in 17-month local control (LC) of 43%, 74%, and 95%, respectively; no dose-response was seen in T1 tumors (13). Koshy et al. also noted a significant interaction between T-stage and BED\textsubscript{10} in their sensitivity analysis, limiting the cohort to patients receiving a BED\textsubscript{10} >100 Gy (5). Using a cutoff of 150 Gy\textsubscript{10}, the 3-year OS among patients with T2 tumors was significantly improved with BED\textsubscript{10} >150 Gy (37% vs. 17%, HR 0.32, P<0.0001), but not among T1 tumors (P=0.952). Moving forward, given that tumor size likely correlates with LC and OS in NSCLC patients who receive SBRT, it should be used to stratify patients for planned subset analysis in prospective studies that evaluate different SBRT regimens. In contrast, lower BED\textsubscript{10} regimens may be appropriate in treating smaller tumors as part of a risk-based approach, with similar efficacy (14). Other settings that may be appropriate for lower dosing include those immediately adjacent to critical OARs and patients with comorbidities or advanced age who may not tolerate the added risk of toxicity (15).

Whether higher doses lead to increased toxicity likely also depends on factors unaccounted for in this analysis, including tumor centrality and individual OAR dose constraints. The report from Timmerman et al. outlined the concern for toxicity among centrally located tumors (16), leading to the adoption of various protracted and/or lower BED regimens attempting to limit toxicity. Recently, Bezjak et al. published outcomes from RTOG 0813, the phase I-II dose-escalation study for central tumors, which confirmed limited toxicity when adhering to strict dose constraints (17). While this may be reasonable for most patients, questions remain about the best dose and fractionation schedule that maximizes LC and minimizes toxicity for patients with tumors that are ultracentral or intimately associated (i.e., GTV or PTV overlap) with central OARs, particularly the proximal bronchial tree and esophagus. Some studies have shown very high rates of Grade 3–5 toxicity with ultracentral tumors, even with protracted fractionation schedules and lower BED\textsubscript{10} (18) or high rates of local failure with tumors treated more conservatively (19).

Although such trade-offs between TCP and toxicity are difficult to navigate, ongoing trials such as the HILUS trial (20) and SUNSET trial (NCT03306680) (21) may provide better information about the risks to make more informed decisions.

Could the inferior survival outcomes of the lower BED regimens be due to a higher proportion of patients with centrally located tumors? While the authors attempted to mitigate the confounding by tumor centrality by limiting the analysis to T2a (size <5 cm) lesions per AJCC 7\textsuperscript{th} edition treated with doses >100 Gy\textsubscript{10}, it is certainly plausible that protracted fractionation schedules with lower BED\textsubscript{10} correlate with tumor centrality, as physicians attempt to reduce toxicities associated with mediastinal and hilar structures while increasing the number of patients eligible for SBRT. Central tumors are associated with an increased risk of occult nodal metastases (22), and the adverse effects of inadequate staging methods, including PET/CT and mediastinal lymph node sampling, may disproportionately affect these patients. This potential for confounding again demonstrates the importance of further prospective evaluation of the association between dose and OS.

As the SBRT data has matured, many suitable fractionation schemes have emerged. Among patients receiving 100 Gy\textsubscript{10} or more, the authors have shown that
from 2004–2014, notable changes in SBRT prescription doses have occurred, including the decline of 3 fraction regimens from its peak in 2007 and an inversely proportional rise of 50 Gy in 5 fractions (4). While these differences are unlikely due to changes in patient presentation, the authors attribute them to significant publications and changes in recommendations. In the absence of convincing data, groups have recommended lower BED regimens, claiming they have similar efficacy with a lower toxicity profile (23), a premise called into question by the present study. Another potential contributing factor is a patient's candidacy for SBRT. Radiation oncologists may be offering SBRT to more patients, including those previously receiving fractionated radiotherapy such as patients with central tumors.

A striking revelation in this analysis is the preference for increasingly protracted fractionation schedules since 2007, shortly after a publication of increased toxicity with central tumors treated with high BED regimens (16). Abruptly, the global radiation oncology community is facing a unique challenge with resource constraints during the SARS COV-2 pandemic. Perhaps it is time to rethink the utilization of more severe hypofractionation schedules. While the authors did not address single-fraction schedules, perhaps due to the breakdown of the linear-quadratic model with large single doses of radiation, this strategy may be particularly attractive during the current crisis. In light of this, two randomized phase II clinical trials supporting the use of single-fraction SBRT in peripheral, early-stage NSCLC are certainly worth noting [NRG/RTOG 0915 (NCT00960999) (24) and Roswell Park (NCT00843726) (25)], as they confirm excellent long term tumor control with low toxicity rates in appropriately selected patients.

In conclusion, while the notion of SBRT regimens needing at least 100 Gy_{10} for definitive treatment in early-stage NSCLC is widely accepted, the superiority of any regimen in any specific clinical scenario remains inconclusive (aside from increased toxicity of central lesions treated in 3 fractions), and yet many clinicians have moved toward lower BED treatment regimens. This work demonstrates that higher BED_{10} regimens are associated with and may lead to improved survival outcomes. Limitations in our understanding of radiobiologic modeling of high dose per fraction treatments may impair our ability to compare outcomes across the various treatment schedules, while currently available studies demonstrate such significant heterogeneity in reporting DVH characteristics of PTVs and OARs that detailed analyses are difficult. The available outcomes suggest that tumor size may influence the required dose to achieve tumor control, and other patient subsets, including the elderly and those with central tumors, may benefit from lower equivalent doses. RTOG 0813 provides robust guidelines for safe delivery of SBRT for centrally located tumors but the percentage of ultracentral tumors was low. Ultimately, a regimen that will yield the most favorable therapeutic ratio for the individual patient should be chosen. Future prospective validation of these treatment characteristics, particularly related to target and OAR DVH characteristics, are needed.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3149). SS reports grants from Varian Industries outside the submitted work; AVL reports personal fees from Varian Medical Systems Inc. outside the submitted work; SSL reports research support from Elekta AB in Elekta Gamma Knife ICON Expert Group outside of submitted work. The other authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


